NCT00225212View on ClinicalTrials.gov

Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 30, 1997

Primary Completion Date

March 31, 2003

Study Completion Date

March 31, 2003

Conditions
Non-Hodgkin's LymphomaDiffuse Large Cell LymphomaMantle Cell LymphomaTransformed LymphomaOther Subtypes of B-cell LymphomaLymphoma
Interventions
DRUG

Rituximab 375 mg/m2

Trial Locations (1)

94305

Stanford University Medical Center, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT00225212 - Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter